Sugi Predict

Sugi Predict / Compounds / SCHEMBL213314

SCHEMBL213314

SCHEMBL213314

CC[C@@H](CO)NC(=O)OCc1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 1/20 0.64
▸ CTRB1 P17538 2/20 0.61
▸ ATM Q13315 1/20 0.53
▸ CTSL P07711 6/20 0.53
▸ CTSS P25774 6/20 0.53
▸ CTSK P43235 5/20 0.53
▸ CTSB P07858 3/20 0.53
▸ MEN1 O00255 1/20 0.51
▸ LMNA P02545 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ ELANE P08246 1/20 0.50
▸ CYP3A4 P08684 2/20 0.49
▸ CYP2D6 P10635 1/20 0.49
▸ CYP2C9 P11712 1/20 0.49
▸ CYP2C19 P33261 1/20 0.49
▸ RAB9A P51151 1/20 0.49
▸ TRPM8 Q7Z2W7 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11528148 1.00 SYK (0.64) SYKCTRB1ATMCTSLCTSS
SCHEMBL2636259 1.00 SYK (0.64) SYKCTRB1ATMCTSLCTSS
Acetic Acid SCHEMBL9810154 0.97 SYK (0.62) SYKCTRB1ATMCTSLCTSS
SCHEMBL12220545 0.92 SYK (0.69) SYKCTRB1ATMCTSLCTSS
SCHEMBL4829896 0.91 CTRB1 (0.68) SYKCTRB1ATMCTSLCTSS
SCHEMBL28366233 0.88 CTRB1 (0.58) SYKCTRB1ATMCTSLCTSS
SCHEMBL21906489 0.88 CTRB1 (0.58) SYKCTRB1ATMCTSLCTSS
SCHEMBL15271597 0.88 CTRB1 (0.58) SYKCTRB1ATMCTSLCTSS
SCHEMBL14595243 0.88 CTRB1 (0.74) SYKCTRB1ATMCTSLCTSS
SCHEMBL8900969 0.88 CTRB1 (0.74) SYKCTRB1ATMCTSLCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4566670-A2 MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS Gilead Sciences, Inc. (US) 2025-06-11 — — EP disclosed
EP-3696171-B1 MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS GILEAD SCIENCES INC (US) 2025-02-19 — — EP disclosed
EP-4403221-A2 MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS Gilead Sciences, Inc. (US) 2024-07-24 — — EP disclosed
EP-2487161-B2 Modulators of pharmacokinetic properties of therapeutics GILEAD SCIENCES INC (US) 2024-06-05 — — EP disclosed
EP-2049506-B2 MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS GILEAD SCIENCES INC (US) 2024-05-08 — — EP disclosed
CN-117402189-A Phosphoramidate (phosphonate) acetals and phospho (phosphonate) acetal compounds 广东集宝医药技术有限公司 2024-01-16 — — CN disclosed
US-20230365533-A1 BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS MERCK SHARP & DOHME LLC (US) 2023-11-16 — — US disclosed
CN-111836818-B Phosphoramidate (phosphonate) acetals and phospho (phosphonate) acetal compounds 纽科利制药公司 2023-10-31 — — CN disclosed
US-20230257348-A1 CYCLOPENTAPYRROLE OREXIN RECEPTOR AGONISTS MERCK SHARP & DOHME LLC (US) 2023-08-17 — — US disclosed
US-11680060-B2 Bicycloheptane pyrrolidine orexin receptor agonists MERCK SHARP & DOHME LLC (US) 2023-06-20 — — US disclosed
US-20080108617-A1 co-administered drug (as HIV protease inhibiting compound, an HIV (non)nucleoside/nucleotide inhibitor of reverse transcriptase, capsid polymerization inhibitor, interferon, ribavirin analog) by inhibiting cytochrome P450 monooxygenase; ureido- or amido-amine derivatives; side effect reduction GILEAD SCIENCES, INC. 2008-05-08 — — US disclosed
WO-2008010921-A2 MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS GILEAD SCIENCES, INC. (US) 2008-01-24 — — WO disclosed
EP-1287006-B1 ANTITUMORAL COMPOUNDS PHARMA MAR SA (ES) 2007-10-24 — — EP disclosed
EP-1287006-B1 ANTITUMORAL COMPOUNDS PHARMA MAR SA (ES) 2007-10-24 — — EP disclosed
US-7138547-B2 Antitumoral compounds PHARMA MAR, S.A. 2006-11-21 — — US disclosed
EP-1340757-B1 1-METHYLCARBAPENEM DERIVATIVES SANKYO CO (JP) 2006-10-11 — — EP disclosed
US-7001897-B2 1-methylcarbapenem derivatives SANKYO COMPANY, LIMITED (JP) 2006-02-21 — — US disclosed
US-20040048834-A1 Antitumoral compounds PHARMA MAR, S.A. (ES) 2004-03-11 — — US disclosed
US-20040014962-A1 1-Methylcarbapenem derivatives SANKYO COMPANY, LIMITED (JP) 2004-01-22 — — US disclosed
EP-1340757-A1 1-METHYLCARBAPENEM DERIVATIVES Sankyo Company, Limited (JP) 2003-09-03 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014962-A1 1-Methylcarbapenem derivatives CD14, CPT1A, ACMSD SYK 622/4885CTRB1 2156/4885ATM 4061/4885
US-20080108617-A1 co-administered drug (as HIV protease inhibiting compound, an HIV (non)nucleoside/nucleotide inhibitor of reverse transcriptase, capsid polymerization inhibitor, interferon, ribavirin analog) by inhibiting cytochrome P450 monooxygenase; ureido- or amido-amine derivatives; side effect reduction PNP, UNG, PNPO SYK 4008/4885CTRB1 177/4885ATM 4027/4885
US-20230365533-A1 BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS HCRTR1, HCRTR2, CRHR1 SYK 4351/4885CTRB1 1454/4885ATM 4876/4885
US-20040048834-A1 Antitumoral compounds HCCS, MSR1, SUCNR1 SYK 2311/4885CTRB1 3693/4885ATM 3873/4885
US-11680060-B2 Bicycloheptane pyrrolidine orexin receptor agonists HCRTR1, HCRTR2, CRHR1 SYK 4230/4885CTRB1 1666/4885ATM 4868/4885
US-20230257348-A1 CYCLOPENTAPYRROLE OREXIN RECEPTOR AGONISTS HCRTR2, HCRTR1, NPY1R SYK 2308/4885CTRB1 2669/4885ATM 4879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.